What is Trellis Bioscience?
Trellis Bioscience is a specialized biotechnology firm focused on the discovery and development of human monoclonal antibodies (mAbs). At the core of its operations is the proprietary CellSpot platform, a technological innovation that enables the rapid identification and characterization of rare, high-affinity antibodies. This platform serves as the foundation for a robust pipeline, including the lead candidate TRL1068, which is designed to address critical medical challenges such as prosthetic joint infections and various viral pathogens. By targeting unmet needs in the pharmaceutical landscape, Trellis Bioscience aims to improve patient outcomes while reducing the reliance on invasive surgical interventions, positioning itself as a vital player in the global health sector.
How much funding has Trellis Bioscience raised?
Trellis Bioscience has raised a total of $28.5M across 4 funding rounds:
Series A
$3.4M
Series B
$10M
Stock/Share Issuance
$6.1M
Series C
$9M
Series A (2004): $3.4M, investors not publicly disclosed
Series B (2007): $10M, investors not publicly disclosed
Stock/Share Issuance (2026): $6.1M, investors not publicly disclosed
Series C (2026): $9M featuring The AMR Action Fund, New Science Ventures, and Easton Capital
Key Investors in Trellis Bioscience
The AMR Action Fund
The AMR Action Fund is dedicated to overcoming technical and funding barriers in antibiotic development, aiming to ensure a sustainable pipeline of new antibiotics to combat superbugs.
New Science Ventures
New Science Ventures, LLC (NSV) is a venture capital firm that invests in early and late-stage companies utilizing novel scientific approaches in the life sciences and information technology sectors.
Easton Capital
Easton Capital Investment Group manages institutional capital and maintains strategic co-investment relationships, allowing it to participate in significant initial and follow-on rounds of funding.
What's next for Trellis Bioscience?
With the recent infusion of capital, Trellis Bioscience is well-positioned to accelerate its clinical development programs and expand the reach of its CellSpot platform. The strategic focus will likely center on advancing TRL1068 through late-stage clinical trials and exploring new therapeutic applications for its antibody library. As the company navigates the complexities of the pharmaceutical market, the support from specialized investors will be instrumental in navigating regulatory pathways and scaling manufacturing capabilities. The firm's commitment to addressing antimicrobial resistance remains a key differentiator, ensuring that its growth strategy is aligned with both commercial objectives and urgent global health priorities.
See full Trellis Bioscience company page
